Psoriasis - efalizumab and etanercept (TA103)
Fast, easy summary view of NICE guidance on 'psoriasis'
Etanercept should be offered as an option for treating adults with severe plaque psoriasis when:
- other treatments haven't worked (for example, drugs given by injection or orally, that is, by mouth), or
- these other treatments cause a reaction which means that the person shouldn't continue taking them, or
- the person has another condition or uses another medicine that means they should not take these other treatments.
If the person's psoriasis has not shown a measured response to etanercept after 12 weeks, the treatment should be stopped.
The European Medicines Agency (EMEA), the European Union (EU) body which is responsible for monitoring the safety of medicines, has withdrawn the marketing authorisation for MerckSerono's psoriasis drug efalizumab (Raptiva).
The EMEA's Committee for Medicinal Products for Human Use has reviewed possible links between the drug and a rare but deadly brain infection and said the benefits of efalizumab no longer outweigh its risks, because of safety concerns, notably the occurrence of progressive multifocal leukoencephalopathy. As a result the 'British national formulary' has been updated to say that efalizumab should not be prescribed for patients who are not already taking it. Treatment for patients who are taking efalizumab should be reviewed.
Therefore, NICE has withdrawn its guidance on the use of efalizumab for the treatment of adults with psoriasis. Guidance on the use of etanercept for the treatment of adults with psoriasis remains the same and in force.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: psoriasis
This page was last updated: 07 March 2014
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA103 Etanercept ac efalizumab i drin soriasis: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
- Costing report
- Biologic drugs for the treatment of inflammatory disease in rheumatology, dermatology and gastroenterology commissioning guide
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.